Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cyclo Therapeutics Inc
(NQ:
CYTH
)
1.510
+0.040 (+2.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cyclo Therapeutics Inc
< Previous
1
2
3
Next >
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 18, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
March 14, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
March 13, 2024
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
January 29, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
December 27, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
December 18, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
December 14, 2023
Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
November 21, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
November 15, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
October 30, 2023
Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunities
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million
October 23, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
October 05, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Intercept Pharmaceuticals, Inc. (Nasdaq – ICPT), Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc. (Nasdaq - AMTI), NextGen Healthcare, Inc. (Nasdaq –
September 26, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc. (Nasdaq - AMTI), NextGen Healthcare, Inc. (Nasdaq – NXGN), Computer Task Group, Incorporated (Nasdaq -
September 21, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
CYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to Shareholders
September 21, 2023
From
Halper Sadeh LLC
Via
Business Wire
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
September 21, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results
August 15, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
August 02, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
June 29, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
June 13, 2023
Since the end of the third quarter, we made an initial $2.1 million investment in Cyclo Therapeutics, Inc. (Nasdaq: CYTH) and have an agreement to increase our investment by $5 million
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer’s Disease
June 12, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement
June 05, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
May 15, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)
May 02, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
April 21, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results
March 20, 2023
From
Cyclo Therapeutics
Via
Business Wire
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
January 11, 2023
Via
ACCESSWIRE
Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements
January 11, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
January 10, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease
January 09, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.